Conversion of cyclosporine to tacrolimus in stable renal allograft recipients: Quantification of effects on the severity of gingival enlargement and hirsutism and patient-reported outcomes

Nephrology

Volumn 12, Issue 6, 2007, Pages 607-614

  Walker, Rowan G ^a,c   Cottrell, Stephen ^a   Sharp, Kathleen ^a   Tripodi, Rosamaria ^a   Nicholls, Kathy M ^a   Fraser, Ian ^a   Varigos, George A ^a   Butcher, Belinda E ^b  

^a ROYAL MELBOURNE HOSPITAL   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Cyclosporine; Gingival enlargement; Hirsutism; Tacrolimus; Transplant

Indexed keywords

AMLODIPINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DILTIAZEM; NIFEDIPINE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACE DEFORMITY; FEMALE; GINGIVA HYPERPLASIA; GINGIVAL ENLARGEMENT; GINGIVITIS; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HIRSUTISM; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOOTH PLAQUE;

CYCLOSPORINE; GINGIVAL DISEASES; HIRSUTISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 35848951848     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00884.x     Document Type: Article

References (21)

1. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. Am. J. Health Syst. Pharm. 2005 62 : 1775 81.
2. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of ciclosporine-A and tacrolimus. Clin. Nephrol. 1998 49 : 356 63.
3. Tanabe K. Calcineurin inhibitors in renal transplantation: What is the best option? Drugs 2003 63 : 1535 48.
4. Sanson-Fisher RW, Perkins JJ. Adaptation and validation of the SF-36 Health Survey for use in Australia. J. Clin. Epidemiol. 1998 51 : 961 7.
5. Loee H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol. Scand. 1963 21 : 533 51.
6. Silness J, Loee H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol. Scand. 1964 22 : 121 35.
7. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J. Clin. Periodontol. 1993 20 : 286 93.
8. McGaw T, Lam S, Coates J. Cyclosporin-induced gingival overgrowth: Correlation with dental plaque scores, gingivitis scores, and cyclosporin levels in serum and saliva. [Erratum appears in Oral Surg Oral Med Oral Pathol June 1988; 65: 684.] Oral Surg. Oral Med. Oral Pathol. 1987 64 : 293 7.
9. Seymour RA, Smith DG, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J. Clin. Periodontol. 1985 12 : 413 19.
10. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2003. Geneva : World Health Organization, 2003.
11. Margreiter R, Pohanka E, Sparacino V et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transpl. Int. 2005 18 : 816 23.
12. Hernandez G, Arriba L, Lucas M, de Andres A. Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus. J. Periodontol. 2000 71 : 1630 36.
13. Kohnle M, Lutkes P, Witzke O, Philipp T, Heemann U. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. Transplant. Proc. 1998 30 : 2122 3.
14. Vescovi P, Meleti M, Manfredi M, Merigo E, Pedrazzi G. Cyclosporin-induced gingival overgrowth: A clinical-epidemiological evaluation of 121 Italian renal transplant recipients. J. Periodontol. 2005 76 : 1259 64.
15. Abdollahi M, Radfar M. A review of drug-induced oral reactions. J. Contemp. Dent. Pract. 2003 4 : 10 31.
16. Chand DH, Quattrocchi J, Poe SA, Terezhalmy GT, Strife CF, Cunningham RJ. Trial of metronidazole vs. azithromycin for treatment of cyclosporine-induced gingival overgrowth. Pediatr. Transplant. 2004 8 : 60 64.
17. Mesa FL, Osuna A, Aneiros J et al. Antibiotic treatment of incipient drug-induced gingival overgrowth in adult renal transplant patients. J. Periodontal Res. 2003 38 : 141 6.
18. Nash MM, Zaltzman JS. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. [see comment.] Transplantation 1998 65 : 1611 15.
19. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002 359 : 741 6.
20. Shield CF III, McGrath MM, Goss TF. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. Fk506 Kidney Transplant Study Group. Transplantation 1997 64 : 1738 43.
21. Peters TG, Spinola KN, West JC et al. Differences in patient and transplant professional perceptions of immunosuppression-induced cosmetic side effects. Transplantation 2004 78 : 537 43.